Hogan Lovells 2024 Election Impact and Congressional Outlook Report
Area of focus
You purchase rights, assets, and companies to build your business. The lawyers at Hogan Lovells advise global life sciences companies on the most sophisticated transactions.
Routinely conduct due diligence of FDA and foreign regulatory law for a wide variety of corporate clients involved in Initial Public Offerings (IPOs) and other types of financings to corporate acquisitions.
Frequently help draft and revise the regulatory sections of security disclosure documents for many of our public company clients.
Conducted U.S. due diligence on FDA, intellectual property, and antitrust issues for a major pharmaceutical client's billion dollar, multinational acquisition of a major pharmaceutical product.
Provided U.S. and EU regulatory due diligence for numerous clients, including investment firms considering investments or loans to non-client companies with novel products.
A product considered for acquisition by an animal health industry client was at high risk of never being approved or having a major delay due to the sponsor needing to conduct in-depth environmental assessments.
Evaluated a proposed purchase of a veterinary medicinal product from the standpoint of EU and United Kingdom regulatory law.
Band 1 for Healthcare: Pharmaceutical/Medical Products Regulatory in the District of Columbia
Chambers USA
Band 1 in Brussels in EU Regulatory for Pharmaceutical and Biotechnology
Legal 500 EMEA
Band 2 in France for Pharma/Life Sciences
Chambers Europe-wide
Band 2 Regulatory: Life Sciences/Pharma
Chambers Europe-wide